PharmaCyte Biotech, Inc.
PMCB
$0.55
$0.000.73%
NASDAQ
| 04/30/2026 | 01/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -55.56% | 63.97% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -54.59% | 53.92% | |||
| Operating Income | 54.59% | -53.92% | |||
| Income Before Tax | -688.22% | 110.07% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -688.22% | 110.07% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -688.22% | 110.07% | |||
| EBIT | 54.59% | -53.92% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -172.14% | 86.44% | |||
| Normalized Basic EPS | 255.67% | 91.19% | |||
| EPS Diluted | -444.40% | 86.44% | |||
| Normalized Diluted EPS | 255.67% | 91.19% | |||
| Average Basic Shares Outstanding | 15.07% | 36.30% | |||
| Average Diluted Shares Outstanding | 15.07% | 36.30% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -1.14% | 17.44% | |||